A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments

Prior treatment

• Participants with a concomitant cancer at the time of diagnosis of NSCLC (except for non-metastatic non-melanoma skin cancers, in situ or benign neoplasms). Occurrence of cancer within 5 years after NSCLC diagnosis will be considered as secondary cancer.

Other illness

• Having records of participation or past participation in clinical trial for lung cancer within the data collection period of the study.
• Histology of the tumor is small cell lung cancer, neuroendocrine in origin, or a mixed histologic type with small cell and non-small cell lung cancers.

Other

• This study excludes participants who met any of the following criteria.
• Participants with significantly missing medical record data or patients deemed inappropriate for inclusion by investigators.

• Participants aged ≥18 years when diagnosed with advanced NSCLC.
• Histologically or cytologically confirmed stage IV NSCLC.
• For non-AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31, 2022, and participants received corresponding immunotherapy in the first or second line.
• For AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31, 2022. Among them, participants with documented positive result for EGFR, ALK, or ROS1 testing received corresponding targeted therapy in the first or second line.